Navigation Links
Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD
Date:10/29/2008

red to placebo.(2)

-- The incidence of other potential lung infections (e.g., bronchitis) was generally higher for all active treatment groups, except SYMBICORT 80/4.5 mcg, compared to placebo.(2)

-- The most common drug-related adverse events were oral candidiasis, dysphonia, a voice disorder,(7) and headache.(2)

SUN Study Results (Abstracts 303 and 308)

The long-term efficacy and tolerability of SYMBICORT was assessed in a 12-month, randomized, double-blind, multicenter study evaluating 1,964 patients ages 40 years and older with moderate to very severe COPD.(3,4) After two weeks of treatment based on previous therapy (ICS and short-acting bronchodilators were allowed), patients were then randomized to receive twice-daily treatment with two inhalations of SYMBICORT pMDI 160/4.5 mcg, SYMBICORT pMDI 80/4.5 mcg, formoterol DPI 4.5 mcg or placebo.(3,4) Study results include:

-- SYMBICORT 160/4.5 mcg demonstrated significantly (P Less Than or Equal To .023) greater improvements from baseline in pre-dose FEV1 and one-hour post-dose FEV1 compared with formoterol.(3)

-- Improvements from baseline in morning and evening PEF were significantly (P Less Than or Equal To .017) greater for both SYMBICORT doses compared with formoterol and placebo.(3)

-- Exacerbation rates were significantly (P Less Than or Equal To .004) reduced by approximately 25-30 percent with both doses of SYMBICORT compared to formoterol and by approximately 40 percent compared to placebo.(3)

-- Both SYMBICORT doses demonstrated significantly (P<.038) greater improvements in BCSS (160/4.5 mcg only), sleep score, awakening-free nights (80/4.5 mcg only), and rescue medication use versus formoterol.(3)

-- Both doses of SYMBICORT were well-tolerated versus formoterol and placebo for up to 12 months.(4) The incidence of pneumonia-related adverse events were similar for all treatment arms compared to placebo.(4)

-- The incidence of other pote
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
5. Recruitment Completed in Ofatumumab NHL Pivotal Study
6. Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs
7. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
8. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
9. 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
10. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
11. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... 23, 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ... integrated healthcare enterprise, today announced that the Group has accumulated ... Corporation ("CCBC," - CO.US) from the open market between December ... Group now owns 39.5% of the issued share capital of ...
... Four hospitals serving Virginia patients reduced healthcare-acquired infection rates ... in savings of $1.2 million in additional costs to ... plan to existing federal hand washing protocols, these hospitals ... and reduced patient length-of-stay and unnecessary readmissions. ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... 28, 2014 Dr. Andrew Campbell, one ... announced the expansion of Quintessa Aesthetic Center into a ... located at W307 N1497 Golf Road in Suite 200 ... Dr. Campbell, the new Delafield location will offer a ... patients, including: Botox, filler injectables , micro laser ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic surgeons ... for those in the area that would like to learn more ... will take place on December 11, 2014, from 6:00 p.m. until ... Houston at 4208 Richmond Ave. , “We want to wish ... and celebrate the season with us on December 11, 2014 from ...
(Date:11/28/2014)... Evergreen, Colorado (PRWEB) November 28, 2014 Written ... Jackson , Brook Forest Voices releases the “The Happiest ... audiobook , a compelling account of how and why Project ... of Idaho by his mother Josie and the Reverend Richard ... millionaire by the age of 30, but realized that he ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter , ... in the kitchen, through cooking classes or at home, may ... a recent review. Cooking programs and classes for children ... to the new research. And, although the review didn,t look ... such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... , , WEDNESDAY, April 22 (HealthDay News) -- Responding to ... Administration said Wednesday that it will now allow 17-year-olds ... a doctor,s prescription. , In 2006, the FDA ... also known as Plan B, to women 18 and ...
... 22 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... New Jersey based company focused on clinical approval of ... disc replacement device. This strategic acquisition allows NuVasive the ...
... TMK ) reported today that for the quarter ... (after a charge of $.49 per share for impairment of ... quarter. Net operating income for the quarter was $1.49 ... per share for the year-ago quarter. Reconciliations between net income ...
... of drinking while pregnant, , , WEDNESDAY, April 22 (HealthDay ... and mental problems in babies born to women who ... known that drinking while pregnant can be harmful to ... to children with noticeable deficits, noted Chris Downing, a ...
... AMICAS, Inc. (Nasdaq: AMCS ), a ... solutions, today announced it will report the company,s financial ... after the market closes on Monday, May 11, 2009.(Logo: ... of its financial results, management will host a conference ...
... To Webcast Annual Shareholders MeetingLIONVILLE, Pa., April 22 ... announced today that it will release 2009 first quarter ... 30, 2009, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ...
Cached Medicine News:Health News:FDA Approves 'Plan B' Pill for 17-Year-Olds 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 2Health News:Torchmark Corporation Reports First Quarter 2009 Results 3Health News:Torchmark Corporation Reports First Quarter 2009 Results 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 5Health News:Torchmark Corporation Reports First Quarter 2009 Results 6Health News:Torchmark Corporation Reports First Quarter 2009 Results 7Health News:Torchmark Corporation Reports First Quarter 2009 Results 8Health News:Torchmark Corporation Reports First Quarter 2009 Results 9Health News:Torchmark Corporation Reports First Quarter 2009 Results 10Health News:Torchmark Corporation Reports First Quarter 2009 Results 11Health News:Torchmark Corporation Reports First Quarter 2009 Results 12Health News:AMICAS Schedules First Quarter 2009 Earnings Results Conference Call 2Health News:West to Host 2009 First Quarter Conference Call 2
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
... wide orifice tip, the Finntip Wide is ... and macromolecules like genomic DNA. This tip ... fragmentation. It is excellent for use with ... the inside diameter of the orifice is ...
... designed to optimize the accuracy and precision ... products is widely recognized by customers throughout ... extended over the years and now covers ... tips including filter tips, certified pure tips, ...
... plastic-wrapped racks of 96 tips, Sterilized Diamond- ... autoclave. Sterilized Diamond Tips are irradiated by ... delivered with a certificate of sterilization, specifying ... are certified free of detectable Rnase, Dnase, ...
Medicine Products: